PPD Earns Highest Ratings for Customer Loyalty and Overall Value among Phase I Providers in ISR Report

Top marks in other service areas show the company’s performance typically exceeds customer expectations

PPD Earns Highest Ratings for Customer Loyalty and Overall Value among Phase I Providers in ISR Report

<0> PPDMedia:Randy Buckwalter, +1 919 456 4425orInvestors:Luke Heagle, +1 910 558 7585 </0>

Pharmaceutical Product Development, LLC (PPD) has earned the highest ratings in customer loyalty, overall value and several other attributes for according to an Industry Standard Research (ISR) study, which evaluated 12 Phase I providers across nine key areas.

In its new report, “,” ISR surveyed 61 pharmaceutical executives responsible for Phase I outsourcing. In the survey, PPD received the highest rating for customer loyalty, a result of its top scores for overall satisfaction, willingness to recommend and likelihood to use again. In addition, PPD received the highest marks for five of ISR’s nine service attributes, including overall value, technical expertise, breadth of services, meeting schedules and timelines, and quality of the Phase I unit’s lead investigator—demonstrating that the company’s performance surpasses customer expectations.

“Our Phase I team is committed to assuring the safety of our volunteers and providing the highest level of service for our clients, and ISR’s data affirms the outstanding efforts of this team,” said Lee Babiss, Ph.D., executive vice president of global lab services and chief scientific officer for PPD. “The long tenure and expertise of our management team are key differentiators for PPD and are critical factors in the overall value we deliver our clients.”

PPD has one of the world’s largest and has been performing Phase I studies on normal healthy volunteers for 27 years. With a state-of-the-art, 300-bed facility located in Austin, Texas, the clinic has the capability to conduct multiple studies simultaneously across all therapeutic areas.

ISR is a full-service market research provider to the pharmaceutical and pharmaceutical services industries. In addition to the ratings, the Phase I services report includes an analysis of biopharmaceutical companies’ Phase I outsourcing behaviors, attitudes, beliefs and intentions. It also ranks characteristics that are used to select clinical pharmacology service providers.

PPD is a leading global providing , development and lifecycle management services. Our clients and partners include , , , academic and organizations. With offices in 46 countries and more than 12,000 professionals worldwide, PPD applies innovative technologies, therapeutic expertise and a commitment to quality to help clients and partners accelerate the delivery of safe and effective therapeutics and maximize the returns on their R&D investments. For more information, visit .

Suggested Articles

Akero's FGF21 analog beat placebo at reducing liver fat in patients with nonalcoholic steatohepatitis (NASH).

Amgen has become the latest biopharma to try to figure out the hit it may take to its pipeline timings amid the COVID-19 pandemic.

The database was locked at the end of February but will only be unblinded after the FDA has provided feedback.